Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias

C. I. Haffajee, J. C. Love, A. T. Canada, L. J. Lesko, G. Asdourian, Joseph S Alpert

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Using a high-pressure liquid chromatographic assay, we measured serum amiodarone concentrations serially in 122 patients treated with amiodarone for 1.5-53 months (mean 9.3 months) for control of refractory symptomatic atrial or symptomatic and life-threatening ventricular tachyarrhythmias. The atrial tachyarrhythmias were successfully controlled in 45 of 54 patients (83%) during a mean follow-up of 10.0 months. In the ventricular tachyarrhythmia group, which included 22 survivors of sudden cardiac death, 38 of 50 patients (76%) responded to amiodarone during a mean follow-up of 10.9 months. Although the mean serum amiodarone concentration did not differ between responders and nonresponders, eight responders relapsed when their serum concentration fell below 1.0 mg/l. Side effects resulted in withdrawal of amiodarone in only 10 of 122 patients (9%) despite a 30% overall incidence of side effects. Central nervous system and gastrointestinal side effects became more frequent with serum concentrations > 2.5 mg/l, although only central nervous system side effects achieved statistical significance. Absorption and disposition kinetics of a single oral 800-mg dose of amiodarone were studied in eight patients. Serum values were measured for 24 hours in five patients during maintenance therapy, and elimination kinetics after long-term therapy were evaluated in three patients. The tissue concentration of amiodarone was determined in two patients who died during long-term amiodarone therapy and an attempt was made in 14 patients to correlate serum concentrations with daily dosages during maintenance therapy. The pharmacokinetics of oral amiodarone support the practice of using high loading dosages until arrhythmia suppression or apparent steady state is achieved (usually 2-4 weeks), followed by low-dose maintenance therapy (200-600 mg once a day) for treatment of symptomatic atrial and ventricular tachyarrhythmias.

Original languageEnglish (US)
Pages (from-to)1347-1355
Number of pages9
JournalCirculation
Volume67
Issue number6 I
StatePublished - 1983
Externally publishedYes

Fingerprint

Amiodarone
Tachycardia
Pharmacokinetics
Serum
Therapeutics
Central Nervous System
Sudden Cardiac Death
Survivors
Cardiac Arrhythmias
Pressure
Incidence

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Haffajee, C. I., Love, J. C., Canada, A. T., Lesko, L. J., Asdourian, G., & Alpert, J. S. (1983). Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation, 67(6 I), 1347-1355.

Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. / Haffajee, C. I.; Love, J. C.; Canada, A. T.; Lesko, L. J.; Asdourian, G.; Alpert, Joseph S.

In: Circulation, Vol. 67, No. 6 I, 1983, p. 1347-1355.

Research output: Contribution to journalArticle

Haffajee, CI, Love, JC, Canada, AT, Lesko, LJ, Asdourian, G & Alpert, JS 1983, 'Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias', Circulation, vol. 67, no. 6 I, pp. 1347-1355.
Haffajee CI, Love JC, Canada AT, Lesko LJ, Asdourian G, Alpert JS. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation. 1983;67(6 I):1347-1355.
Haffajee, C. I. ; Love, J. C. ; Canada, A. T. ; Lesko, L. J. ; Asdourian, G. ; Alpert, Joseph S. / Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. In: Circulation. 1983 ; Vol. 67, No. 6 I. pp. 1347-1355.
@article{4f6f006c68eb4dee869aadbc35b7b0a7,
title = "Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias",
abstract = "Using a high-pressure liquid chromatographic assay, we measured serum amiodarone concentrations serially in 122 patients treated with amiodarone for 1.5-53 months (mean 9.3 months) for control of refractory symptomatic atrial or symptomatic and life-threatening ventricular tachyarrhythmias. The atrial tachyarrhythmias were successfully controlled in 45 of 54 patients (83{\%}) during a mean follow-up of 10.0 months. In the ventricular tachyarrhythmia group, which included 22 survivors of sudden cardiac death, 38 of 50 patients (76{\%}) responded to amiodarone during a mean follow-up of 10.9 months. Although the mean serum amiodarone concentration did not differ between responders and nonresponders, eight responders relapsed when their serum concentration fell below 1.0 mg/l. Side effects resulted in withdrawal of amiodarone in only 10 of 122 patients (9{\%}) despite a 30{\%} overall incidence of side effects. Central nervous system and gastrointestinal side effects became more frequent with serum concentrations > 2.5 mg/l, although only central nervous system side effects achieved statistical significance. Absorption and disposition kinetics of a single oral 800-mg dose of amiodarone were studied in eight patients. Serum values were measured for 24 hours in five patients during maintenance therapy, and elimination kinetics after long-term therapy were evaluated in three patients. The tissue concentration of amiodarone was determined in two patients who died during long-term amiodarone therapy and an attempt was made in 14 patients to correlate serum concentrations with daily dosages during maintenance therapy. The pharmacokinetics of oral amiodarone support the practice of using high loading dosages until arrhythmia suppression or apparent steady state is achieved (usually 2-4 weeks), followed by low-dose maintenance therapy (200-600 mg once a day) for treatment of symptomatic atrial and ventricular tachyarrhythmias.",
author = "Haffajee, {C. I.} and Love, {J. C.} and Canada, {A. T.} and Lesko, {L. J.} and G. Asdourian and Alpert, {Joseph S}",
year = "1983",
language = "English (US)",
volume = "67",
pages = "1347--1355",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6 I",

}

TY - JOUR

T1 - Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias

AU - Haffajee, C. I.

AU - Love, J. C.

AU - Canada, A. T.

AU - Lesko, L. J.

AU - Asdourian, G.

AU - Alpert, Joseph S

PY - 1983

Y1 - 1983

N2 - Using a high-pressure liquid chromatographic assay, we measured serum amiodarone concentrations serially in 122 patients treated with amiodarone for 1.5-53 months (mean 9.3 months) for control of refractory symptomatic atrial or symptomatic and life-threatening ventricular tachyarrhythmias. The atrial tachyarrhythmias were successfully controlled in 45 of 54 patients (83%) during a mean follow-up of 10.0 months. In the ventricular tachyarrhythmia group, which included 22 survivors of sudden cardiac death, 38 of 50 patients (76%) responded to amiodarone during a mean follow-up of 10.9 months. Although the mean serum amiodarone concentration did not differ between responders and nonresponders, eight responders relapsed when their serum concentration fell below 1.0 mg/l. Side effects resulted in withdrawal of amiodarone in only 10 of 122 patients (9%) despite a 30% overall incidence of side effects. Central nervous system and gastrointestinal side effects became more frequent with serum concentrations > 2.5 mg/l, although only central nervous system side effects achieved statistical significance. Absorption and disposition kinetics of a single oral 800-mg dose of amiodarone were studied in eight patients. Serum values were measured for 24 hours in five patients during maintenance therapy, and elimination kinetics after long-term therapy were evaluated in three patients. The tissue concentration of amiodarone was determined in two patients who died during long-term amiodarone therapy and an attempt was made in 14 patients to correlate serum concentrations with daily dosages during maintenance therapy. The pharmacokinetics of oral amiodarone support the practice of using high loading dosages until arrhythmia suppression or apparent steady state is achieved (usually 2-4 weeks), followed by low-dose maintenance therapy (200-600 mg once a day) for treatment of symptomatic atrial and ventricular tachyarrhythmias.

AB - Using a high-pressure liquid chromatographic assay, we measured serum amiodarone concentrations serially in 122 patients treated with amiodarone for 1.5-53 months (mean 9.3 months) for control of refractory symptomatic atrial or symptomatic and life-threatening ventricular tachyarrhythmias. The atrial tachyarrhythmias were successfully controlled in 45 of 54 patients (83%) during a mean follow-up of 10.0 months. In the ventricular tachyarrhythmia group, which included 22 survivors of sudden cardiac death, 38 of 50 patients (76%) responded to amiodarone during a mean follow-up of 10.9 months. Although the mean serum amiodarone concentration did not differ between responders and nonresponders, eight responders relapsed when their serum concentration fell below 1.0 mg/l. Side effects resulted in withdrawal of amiodarone in only 10 of 122 patients (9%) despite a 30% overall incidence of side effects. Central nervous system and gastrointestinal side effects became more frequent with serum concentrations > 2.5 mg/l, although only central nervous system side effects achieved statistical significance. Absorption and disposition kinetics of a single oral 800-mg dose of amiodarone were studied in eight patients. Serum values were measured for 24 hours in five patients during maintenance therapy, and elimination kinetics after long-term therapy were evaluated in three patients. The tissue concentration of amiodarone was determined in two patients who died during long-term amiodarone therapy and an attempt was made in 14 patients to correlate serum concentrations with daily dosages during maintenance therapy. The pharmacokinetics of oral amiodarone support the practice of using high loading dosages until arrhythmia suppression or apparent steady state is achieved (usually 2-4 weeks), followed by low-dose maintenance therapy (200-600 mg once a day) for treatment of symptomatic atrial and ventricular tachyarrhythmias.

UR - http://www.scopus.com/inward/record.url?scp=0020584174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020584174&partnerID=8YFLogxK

M3 - Article

C2 - 6851030

AN - SCOPUS:0020584174

VL - 67

SP - 1347

EP - 1355

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6 I

ER -